[1] Dispenzieri A, Kyle R, Merlini G, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders[J]. Leukemia,2009,23(2):215-224.
[2] Dejoie T, Corre J, Caillon H, et al.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma[J]. Blood,2016, 128(25):2941-2948.
[3] Katzmann JA, Kyle RA, Benson J, et al.Screening pane-ls for detection of monoclonal gammopathies[J]. Clin Chem,2009,55(8):1517-1522.
[4] Holding S, Spradbery D, Hoole R, et al.Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies[J]. Clin Chem Lab Med,2011,49(1):83-88.
[5] 王继贵. 用血清游离轻链分析法检测单克隆γ-病[J]. 实验与检验医学,2014,32(3):233-236.
[6] Abadie JM, Bankson DD.Assessment of serum free light chain assays for plasma cell disorder screening in a Vete-rans Affairs population[J]. Ann Clin Lab Sci,2006,36(2):157-162.
[7] Bradwell AR.Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:30-31.
[8] Matters DJ, Solanki M, Jones R, et al.Statistical analysis of free light chain results between seven nephelometric and turbidimetric platforms[J]. Clin Chem,2008,54:C107a.
[9] Rajkumar SV, Landgren O, Mateos MV.Smoldering multiple myeloma[J]. Blood,2015,125(20):3069-3075.
[10] Bradwell AR.Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:233-234.
[11] Mead GP, Carr-Smith HD, Drayson MT, et al.Serum free light chains for monitoring multiple myeloma[J]. Br J Haematol,2004,126(3):348-354.
[12] Bradwell AR.Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:130-153.
[13] Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al.Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma[J]. Br J Haematol,2007,137(3):240-243.
[14] Snozek CL, Katzmann JA, Kyle RA, et al.Prognostic va-lue of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system[J]. Leukemia,2008,22(10):1933-1937.
[15] Dispenzieri A, Lacy MQ, Katzmann JA, et al.Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation[J]. Blood,2006, 107(8):3378-3383.
[16] Rajkumar SV, Kyle RA, Therneau TM, et al.Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance[J]. Blood,2005,106(3):812-817.
[17] Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, et al.Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy[J]. Leukemia,2015,29(10):2033-2038.
[18] Larsen JT, Kumar SK, Dispenzieri A, et al.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma[J]. Leukemia,2013,27(4):941-946.
[19] Tacchetti P, Cavo M, Rocchi S, et al.Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens[J]. Leuk Lymphoma,2016,57(9):2058-2064.
[20] Hassoun H, Reich L, Klimek VM, et al.The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for Multiple Myeloma[J]. Blood,2005,106:972a.
[21] Durie BG, Harousseau JL, Miguel JS, et al.International uniform response criteria for multiple myeloma[J]. Leukemia,2006,20(9):1467-1473.
[22] Kyle RA, Rajkumar SV.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma[J]. Leukemia,2009,23(1):3-9.
[23] Bradwell AR. Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:61-76,138-142. |
